Who are Ezetimibe 10/Simvastatin 20's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Active comparator1 : Ezetimibe / Rosuvastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ezetimibe-10-simvastatin-20.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ezetimibe 10/Simvastatin 20 — Competitive Intelligence Brief

Ezetimibe 10/Simvastatin 20 (Ezetimibe 10/Simvastatin 20) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination lipid-lowering agent (ezetimibe/statin). Area: Cardiovascular.

marketed Combination lipid-lowering agent (ezetimibe/statin) NPC1L1 (ezetimibe); HMG-CoA reductase (simvastatin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ezetimibe 10/Simvastatin 20 (Ezetimibe 10/Simvastatin 20) — University Hospital Freiburg. This combination reduces cholesterol by blocking intestinal cholesterol absorption (ezetimibe) and inhibiting hepatic cholesterol synthesis (simvastatin).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ezetimibe 10/Simvastatin 20 TARGET	Ezetimibe 10/Simvastatin 20	University Hospital Freiburg	marketed	Combination lipid-lowering agent (ezetimibe/statin)	NPC1L1 (ezetimibe); HMG-CoA reductase (simvastatin)
Active comparator1 : Ezetimibe / Rosuvastatin	Active comparator1 : Ezetimibe / Rosuvastatin	Hanlim Pharm. Co., Ltd.	phase 3	Combination lipid-lowering agent (ezetimibe/statin)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (rosuvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination lipid-lowering agent (ezetimibe/statin) class)

Hanlim Pharm. Co., Ltd. · 1 drug in this class
University Hospital Freiburg · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ezetimibe 10/Simvastatin 20 — Competitive Intelligence Brief. https://druglandscape.com/ci/ezetimibe-10-simvastatin-20. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab